XOMA Royalty (XOMA) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for XOMA Royalty (NASDAQ: XOMA):

• 2/24/2026 – XOMA Royalty had its “outperform” rating reaffirmed by Leerink Partners.
• 2/24/2026 – XOMA Royalty had its price target raised by Leerink Partners from $45.00 to $50.00. They now have an “outperform” rating on the stock.
• 2/13/2026 – XOMA Royalty was upgraded by TD Cowen to “hold”.
• 2/9/2026 – XOMA Royalty was upgraded by Zacks Research from “strong sell” to “hold”.
• 12/29/2025 – XOMA Royalty had its “hold (c-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at XOMA Royalty

In related news, CEO Owen Hughes bought 100,000 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were purchased at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the purchase, the chief executive officer owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. This trade represents a 5,000.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 7.20% of the company’s stock.

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.